MPXI:CC - MPX International Announces that its Malta Subsidiary Alphafarma Operations Ltd. Receives its Medical Cannabis License
(TheNewswire)
TORONTO, ONTARIO – TheNewswire- April 20, 2022 – MPX International Corporation (“ MPXInternational ”, “ MPXI ” or the“ Corporation ”) (CSE:MPXI ) ; ( OTC:MPXOF), a multinational diversifiedcannabis company, is pleased to announce that its Maltese indirectsubsidiary, Alphafarma Operations Ltd. (“ Alphafarma ”) hasreceived its License for the Production of Cannabis for Medicinal andResearch Purposes (the “ Medical Cannabis License ”) issued by the Malta MedicinesAuthority. This follows the attainment of the European Union GoodManufacturing Practice certification (the “ EU-GMP Certification ”) issued by the Medicines Authority of Malta in January2022.
The receipt of the Medical Cannabis License is thefinal requirement for Alphafarma to begin commercial production andexport of finished medical cannabis flower products from Malta intomarkets across Europe and elsewhere .
Alphafarma has already secured EU GMP sourced materialfrom licensed cultivation partners. This will be supplemented withadditional cannabis flower from its South African-based EU-GMP FirstGrowth cultivation facility, likely in late 2023.
The first product has alreadybeen successfully registered in Malta, and it will be launched fordistribution under MPXI’s own Salus BioPharma brand in Q3 2022. Similar entry into other markets such as Germany, Czech Republic,Poland and New Zealand are expected later on in the year.
Through this licensing process, MPXI has become one ofthe very few companies with an EU-GMP Certified and fully licensedcannabis facility which is actually located in the Europeanmarketplace. In line with its expansion plans,Alphafarma has already started working towards applying for a licenseamendment to process cannabis derivatives, such as oils.
“The Medical Cannabis License is a significantmilestone for MPXI’s operations in Europe and MPXI’s internationalgrowth strategy. Our team in Malta has been exceptional in its pursuitof the License and is well positioned for the next phase which is theexport of cannabis flower” said W. Scott Boyes, Chairman, Presidentand CEO of MPXI. “This achievement reinforces our plans to create aglobal cannabis company. MPXI is uniquely positioned to be the onlycannabis company with revenue generating operations in North America,Europe and Asia, which MPXI believes will lead to additional strategicopportunities.”
Karl Bartolo, General Manager and Director ofAlphafarma said “We are extremely proud of our team in Malta forthis incredible achievement, especially through the challengingcircumstances presented by the pandemic. We will continue workingrelentlessly on introducing new technologies and formulations in orderto provide patients and prescribers consistent access to a wideportfolio of medical cannabis products of the highest quality, safetyand efficacy standards.”
About MPX InternationalCorporation
MPX International Corporation is a multinational diversified cannabis company focused on developing and operating assets across theinternational cannabis industry with an emphasis on cultivating,manufacturing and marketing products which include cannabinoids astheir primary active ingredient. With current operations spanning fourcontinents in Canada, Switzerland, South Africa, Malta, Australia andThailand as well as evolving partnership and distributionopportunities in other jurisdictions, MPXI continues to positionitself as an emergent global participant in the cannabisindustry.
Cautionary Statement RegardingForward-Looking Information
This news release includes certain“forward-looking statements” under applicable Canadian securitieslegislation that are not historical facts. Forward-looking statementsinvolve risks, uncertainties, and other factors that could causeactual results, performance, prospects, and opportunities to differmaterially from those expressed or implied by such forward-lookingstatements. Forward-looking statements in this news release include,but are not limited to, MPX International’s objectives andintentions. Forward-looking statements are necessarily based on anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties and otherfactors which may cause actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include, but are not limited to: generalbusiness, economic and social uncertainties; litigation, legislative,environmental and other judicial, regulatory, political andcompetitive developments; delay or failure to receive board,shareholder or regulatory approvals; the Corporation’s ability toeffectively deal with the restrictions, limitations and health issuespresented by the COVID-19 pandemic; future cannabis pricing; cannabis cultivation yields;costs of inputs; its ability to market products successfully to itsanticipated clients; reliance on key personnel and contractedrelationships with third parties; the regulatory environment inAustralia, Canada, Malta, South Africa, Switzerland, Thailand andother international jurisdictions; the ability to complete any futurepotential transactions and the terms and conditions thereof; theapplication of federal, state, provincial, county and municipal laws;and the impact of increasing competition; those additional risks set out in MPXInternational’s public documents filed on SEDAR at www.sedar.com , including its audited annualconsolidated financial statements for the financial years endedSeptember 30, 2021 and 2020, and the corresponding management’sdiscussion and analysis; and other matters discussed in this newsrelease. Although MPX International believes that the assumptions andfactors used in preparing the forward-looking statements arereasonable, undue reliance should not be placed on these statements,which only apply as of the date of this news release, and no assurancecan be given that such events will occur in the disclosed time framesor at all. Except where required by law, MPX International disclaimsany intention or obligation to update or revise any forward-lookingstatement, whether as a result of new information, future events, orotherwise.
For further information about MPXI,please contact:
MPX International Corporation
W. Scott Boyes, Chairman, President andCEO
T: +1-416-840-4703
E: info@mpxinternationalcorp.com
or visit one our websites:
N OT FOR DISTRIBUTION TO NEWSWIRE SERVICES INTHE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANYFAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OFUNITED STATES SECURITIES LAWS
Copyright (c) 2022 TheNewswire - All rights reserved.